Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone

Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone

Background: Secondary prevention in patients with myocardial infarction (MI) is critically important to prevent ischaemic heart failure and reduce social burden. Pioglitazone improves vascular dysfunction and prevents coronary atherosclerosis, mainly via anti-inflammatory and antiatherogenic effects...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EClinicalMedicine 2018-10, Vol.4-5, p.10-24
Hauptverfasser: Asakura, Masanori, Kim, Jiyoong, Asanuma, Hiroshi, Nakama, Yasuharu, Tsukahara, Kengo, Higashino, Yorihiko, Ishikawa, Tetsuya, Koba, Shinji, Tsujimoto, Mitsuru, Himeno, Hideo, Maruyama, Yasuyuki, Ookusa, Takanori, Yoda, Shunichi, Suzuki, Hiroshi, Okubo, Shinji, Shimizu, Makoto, Hashimoto, Yuji, Satake, Kazuo, Fujino, Susumu, Uzui, Hiroyasu, Nagai, Yoshiyuki, Kohno, Tohru, Mizuno, Sumio, Nakahama, Makoto, Kanaya, Hounin, Murohara, Toyoaki, Fukui, Kazuki, Takase, Hiroyuki, Ohte, Nobuyuki, Shiono, Takaaki, Fukunami, Masatake, Endo, Tsutomu, Sawada, Reimin, Fujii, Kenshi, Takeuchi, Motoshi, Ikeda, Shuntaro, Mizuno, Koichi, Uematsu, Masaaki, Matsubara, Taku, Yano, Shoji, Takahashi, Jun, Ueda, Kousei, Kinoshita, Yoshihiko, Tamita, Koichi, Hayashi, Hideki, Hamasaki, Toshimitsu, Kitakaze, Masafumi
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Secondary prevention in patients with myocardial infarction (MI) is critically important to prevent ischaemic heart failure and reduce social burden. Pioglitazone improves vascular dysfunction and prevents coronary atherosclerosis, mainly via anti-inflammatory and antiatherogenic effects by enhancing adiponectin production in addition to antihyperglycemic effects, thus suggesting that pioglitazone attenuates cardiovascular events in patients with mild (HbA1c levels 
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2018.09.006